A prospective study investigating the efficacy of Denosumab for 12 months on glucocorticoid- induced osteoporosis in Japanese patients with rheumatoid arthritis: A Tsurumai Biologics Communication Registry (TBCR)-BONE Trial.
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Denosumab (Primary) ; Prednisolone; Vitamin D
- Indications Osteoporosis; Rheumatoid arthritis
- Focus Therapeutic Use
- 17 Jun 2017 Results (n=63) presented at the 18th Annual Congress of the European League Against Rheumatism.
- 17 Aug 2016 New trial record